{"ATC Code":"J05AG03","Abbreviation":"","Aliases":["Sustiva","Stocrin","DMP-266","(-)-Efavirenz","DMP 266","(S)-Efavirenz","(4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one","Viraday","Efavirenz teva","EFV"],"Biological Half-Life":"40-55 hours","CAS":"154598-52-4","ChEBI":"CHEBI:119486","ChEMBL":"CHEMBL223228","Chirality":"absolute","Color/Form":"Crystals from toluene:heptane","Dosing Info":[],"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antiviral Agents; Anti-HIV Agents; Anti-Retroviral Agents; Reverse Transcriptase Inhibitors","Drug Indication":"For use in combination treatment of HIV infection (AIDS)","Drug Warnings":"To report a case of acquired long QT syndrome that, after exclusion of all other possible causes, was probably related to therapy with efavirenz, a novel nonnucleoside reverse transcriptase inhibitor.","DrugClasses":[],"European Community (EC) Number":"620-492-6","FDA Pharmacological Classification":"JE6H2O27P8","Human Drugs":"Breast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antiviral Agents; Anti-HIV Agents; Anti-Retroviral Agents; Reverse Transcriptase Inhibitors","IUPACName":"(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one","Impurities":["dihydro efavirenz, (e)-","methyl efavirenz","n-(4-methoxybenzyl)efavirenz","6-chloro-4-(3-methylbut-3-en-1-ynyl)-4-(trifluoromethyl)-2h-3,1-benzoxazin-2-one, (s)-","efavirenz pent-3-ene-1-yne, (z)-","6-chloro-2-cyclopropyl-4-(trifluoromethyl)quinoline","n-(4-chloro-2-(4-cyclopropyl-1,1,1-trifluoro-2-hydroxybut-3-yn-2-yl)phenyl)-4-methoxybenzamide, (s)-","efavirenz aminoalcohol","efavirenz, (r)-","efavirenz amino alcohol methyl carbamate","efavirenz pent-3-ene-1-yne, (e)-","sg-275","(2s)-2-(5-chloro-2-((4-methoxyphenyl)methylamino)phenyl)-4-cyclopropyl-1,1,1-trifluorobut-3-yn-2-ol","6-chloro-4-(pent-1-ynyl)-4-(trifluoromethyl)-2h-3,1-benzoxazin-2-one, (s)-","efavirenz amino alcohol ethyl carbamate","efavirenz amino alcohol bis(ethoxycarbonyl)","methyl (4-chloro-2-((2s)-4-cyclopropyl-1,1,1-trifluoro-2-hydroxybut-3-yn-1-yl)phenyl)carbamate"],"InChI":"InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1","InChIKey":"XPOQHMRABVBWPR-ZDUSSCGKSA-N","MeSH Pharmacological Classification":"Drugs and compounds that induce the synthesis of CYTOCHROME P-450 CYP2B6. (See all compounds classified as Cytochrome P-450 CYP2B6 Inducers.)","Melting Point":"139-141 °C","MolecularFormula":"C\u003csub\u003e14\u003c/sub\u003eH\u003csub\u003e9\u003c/sub\u003eClF\u003csub\u003e3\u003c/sub\u003eNO\u003csub\u003e2\u003c/sub\u003e","MolecularWeight":"315.67 g/mol","Opticalactivity":"( - )","Pharmacodynamics":"Efavirenz (dideoxyinosine, ddI) is an oral non-nucleoside reverse transcriptase inhibitor (NNRTI). It is a synthetic purine derivative and, similar to zidovudine, zalcitabine, and stavudine. Efavirenz was originally approved specifically for the treatment of HIV infections in patients who failed therapy with zidovudine. Currently, the CDC recommends that Efavirenz be given as part of a three-drug regimen that includes another nucleoside reverse transcriptase inhibitor (e.g., lamivudine, stavudine, zidovudine) and a protease inhibitor or efavirenz when treating HIV infection.","Physical Description":"Solid","PubChemId":64139,"Record Description":["Efavirenz is 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection. It has a role as a HIV-1 reverse transcriptase inhibitor and an antiviral drug. It is a benzoxazine, an acetylenic compound, an organochlorine compound, an organofluorine compound and a member of cyclopropanes.","Efavirenz is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in adults and in children. Efavirenz is always used in combination with other HIV medicines.","Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.  For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.  Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.","Efavirenz is a Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor. The mechanism of action of efavirenz is as a Non-Nucleoside Reverse Transcriptase Inhibitor, and Cytochrome P450 3A Inducer, and Cytochrome P450 2B6 Inducer, and Cytochrome P450 2C9 Inhibitor, and Cytochrome P450 2C19 Inhibitor, and Cytochrome P450 3A4 Inhibitor.","Efavirenz is a nonnucleoside reverse transcriptase inhibitor used in combination with other agents in the therapy of human immunodeficiency virus (HIV) infection. Efavirenz is associated with a low rate of serum enzyme elevations during therapy and is an uncommon, but well established cause of clinically apparent acute liver injury.","Efavirenz has been reported in Penicillium griseofulvum and Stachybotrys chartarum with data available.","Efavirenz is a synthetic non-nucleoside reverse transcriptase (RT) inhibitor with antiviral activity. Efavirenz binds directly to the human immunodeficiency virus type 1 (HIV-1) RT, an RNA-dependent DNA polymerase, blocking its function in viral DNA replication. In combination with other antiretroviral drugs, this agent has been shown to significantly reduce HIV viral load, retarding or preventing damage to the immune system and reducing the risk of developing AIDS. Efavirenz induces activity of the cytochrome P450 system, accelerating its own metabolism.","EFAVIRENZ is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 5 approved and 10 investigational indications.","See also: Lamivudine; zidovudine; efavirenz (component of); Stavudine; lamivudine; efavirenz (component of) ... View More ...","Efavirenz is 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection. It has a role as a HIV-1 reverse transcriptase inhibitor and an antiviral drug. It is a benzoxazine, an acetylenic compound, an organochlorine compound, an organofluorine compound and a member of cyclopropanes.","LiverTox|Antimicrobial|Antiviral: HIV|NNRTI"],"References":[{"name":"Wikipedia","url":"https://en.wikipedia.org/wiki/Efavirenz"},{"name":"Wikidata","url":"https://www.wikidata.org/wiki/Q422645"},{"name":"DrugBank","url":"https://go.drugbank.com/drugs/DB00625"},{"name":"PubChem","url":"https://pubchem.ncbi.nlm.nih.gov/compound/64139"},{"name":"ChemSpider","url":"https://www.chemspider.com/Chemical-Structure.3091.html"},{"name":"ChEMBL","url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL223228"},{"name":"ChEBI","url":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:119486"},{"name":"Common Chemistry","url":"https://commonchemistry.cas.org/detail?cas_rn=154598-52-4"},{"name":"HMDB","url":"https://hmdb.ca/metabolites/HMDB0014763"},{"name":"KEGG","url":"https://www.kegg.jp/entry/C08088"},{"name":"UNII","url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/JE6H2O27P8"},{"name":"EPA DSSTox","url":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID9046029"}],"SMILES":"C1CC1C#C[C@]2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F","Solubility":"Practically insoluble in water (less than 10 mg/L)","StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="90.047mm" version="1.2" viewBox="0 0 87.407 90.047" width="87.407mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#90E050" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="91.0" stroke="none" width="88.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="26.147" x2="14.471" y1="88.994" y2="79.199"/>
                  
            <line class="bond" id="mol1bnd2" x1="14.471" x2="28.798" y1="79.199" y2="73.978"/>
                  
            <line class="bond" id="mol1bnd3" x1="26.147" x2="28.798" y1="88.994" y2="73.978"/>
                  
            <path class="bond" d="M28.791 74.318c-.08 .0 -.16 -.023 -.218 -.072c-.134 -.113 -.156 -.359 -.043 -.493l9.795 -11.676c.066 -.067 .18 -.109 .29 -.109c.075 -.0 .148 .02 .203 .066c.134 .112 .156 .359 .043 .493l-9.795 11.675c-.063 .076 -.17 .116 -.275 .116z" fill="#000000" id="mol1bnd4" stroke="none"/>
                  
            <g class="bond" id="mol1bnd5">
                        
                <line x1="38.593" x2="48.388" y1="62.302" y2="50.626"/>
                        
                <line x1="36.725" x2="46.52" y1="60.735" y2="49.059"/>
                        
                <line x1="40.461" x2="50.256" y1="63.869" y2="52.194"/>
                      
            </g>
                  
            <path class="bond" d="M58.451 39.176l-.537 -.45l-11.135 10.551l1.609 1.349l1.609 1.35z" fill="#000000" id="mol1bnd6" stroke="none"/>
                  
            <line class="bond" id="mol1bnd7" x1="58.183" x2="44.975" y1="38.951" y2="31.331"/>
                  
            <g class="bond" id="mol1bnd8">
                        
                <line x1="44.975" x2="44.975" y1="31.331" y2="16.091"/>
                        
                <line x1="42.536" x2="42.536" y1="29.922" y2="17.499"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd9" x1="44.975" x2="31.767" y1="16.091" y2="8.471"/>
                  
            <g class="bond" id="mol1bnd10">
                        
                <line x1="31.767" x2="18.559" y1="8.471" y2="16.091"/>
                        
                <line x1="31.767" x2="20.997" y1="11.286" y2="17.499"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd11" x1="18.559" x2="18.559" y1="16.091" y2="31.331"/>
                  
            <g class="bond" id="mol1bnd12">
                        
                <line x1="18.559" x2="31.767" y1="31.331" y2="38.951"/>
                        
                <line x1="20.997" x2="31.767" y1="29.922" y2="36.136"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd13" x1="44.975" x2="31.767" y1="31.331" y2="38.951"/>
                  
            <line class="bond" id="mol1bnd14" x1="18.559" x2="6.875" y1="31.331" y2="38.079"/>
                  
            <line class="bond" id="mol1bnd15" x1="44.975" x2="55.029" y1="16.091" y2="10.29"/>
                  
            <line class="bond" id="mol1bnd16" x1="61.336" x2="71.391" y1="10.29" y2="16.091"/>
                  
            <g class="bond" id="mol1bnd17">
                        
                <line x1="70.171" x2="80.697" y1="15.387" y2="9.308"/>
                        
                <line x1="71.391" x2="81.917" y1="17.499" y2="11.419"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="80.697" x2="75.434" y1="9.308" y2="12.3475"/>
                <line class="hi" stroke="#FF0D0D" x1="81.917" x2="76.654" y1="11.419" y2="14.459"/>
            </g>
                  
            <line class="bond" id="mol1bnd18" x1="71.391" x2="71.391" y1="16.091" y2="27.409"/>
                  
            <line class="bond" id="mol1bnd19" x1="58.183" x2="68.109" y1="38.951" y2="33.224"/>
                  
            <g class="bond" id="mol1bnd20">
                        
                <line x1="58.451" x2="57.914" y1="38.726" y2="39.176"/>
                        
                <line x1="60.307" x2="59.323" y1="40.484" y2="41.309"/>
                        
                <line x1="62.163" x2="60.732" y1="42.243" y2="43.443"/>
                        
                <line x1="64.019" x2="62.141" y1="44.001" y2="45.576"/>
                        
                <line x1="65.875" x2="63.55" y1="45.76" y2="47.709"/>
                        
                <line x1="67.73" x2="64.959" y1="47.518" y2="49.843"/>
                        
                <line x1="69.586" x2="66.368" y1="49.277" y2="51.976"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd21" x1="67.977" x2="58.697" y1="50.626" y2="58.412"/>
                  
            <line class="bond" id="mol1bnd22" x1="67.977" x2="75.506" y1="50.626" y2="59.601"/>
                  
            <line class="bond" id="mol1bnd23" x1="67.977" x2="77.214" y1="50.626" y2="42.878"/>
                  
            <path class="atom" d="M2.906 37.137q-.786 .0 -1.239 .53q-.452 .524 -.452 1.447q-.0 .91 .417 1.446q.422 .53 1.268 .53q.321 .0 .607 -.053q.291 -.06 .565 -.143v.535q-.274 .102 -.565 .149q-.292 .054 -.697 .054q-.744 -.0 -1.25 -.31q-.5 -.309 -.75 -.875q-.25 -.571 -.25 -1.339q.0 -.744 .268 -1.31q.274 -.566 .804 -.881q.529 -.322 1.279 -.322q.78 .0 1.352 .286l-.244 .524q-.226 -.101 -.506 -.184q-.274 -.084 -.607 -.084zM5.662 41.56h-.601v-5.215h.601v5.215z" fill="#1FF01F" id="mol1atm13" stroke="none"/>
                  
            <g class="atom" id="mol1atm14">
                        
                <path d="M60.123 10.921h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.023 .357 .023 .732v2.739h-.565v-4.9h.714l2.608 4.054h.029q-.006 -.107 -.017 -.327q-.012 -.221 -.024 -.476q-.006 -.262 -.006 -.483v-2.768h.577v4.9z" fill="#3050F8" stroke="none"/>
                        
                <path d="M59.986 5.459h-.619v-2.286h-2.512v2.286h-.613v-4.899h.613v2.072h2.512v-2.072h.619v4.899z" fill="#3050F8" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M86.847 8.466q-.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.757 -.0 -1.263 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.733 -.0 1.233 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM82.983 8.466q.0 .922 .387 1.458q.393 .53 1.221 .53q.839 .0 1.22 -.53q.387 -.536 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" fill="#FF0D0D" id="mol1atm16" stroke="none"/>
                  
            <path class="atom" d="M73.65 31.328q-.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.757 -.0 -1.263 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.733 -.0 1.233 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM69.786 31.328q.0 .923 .387 1.458q.393 .53 1.221 .53q.839 .0 1.22 -.53q.387 -.535 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" fill="#FF0D0D" id="mol1atm17" stroke="none"/>
                  
            <path class="atom" d="M55.549 62.871h-.613v-4.9h2.732v.542h-2.119v1.739h1.994v.541h-1.994v2.078z" id="mol1atm19" stroke="none"/>
                  
            <path class="atom" d="M77.019 64.752h-.613v-4.9h2.732v.542h-2.119v1.738h1.994v.542h-1.994v2.078z" id="mol1atm20" stroke="none"/>
                  
            <path class="atom" d="M78.9 43.281h-.613v-4.899h2.732v.542h-2.119v1.738h1.994v.542h-1.994v2.077z" id="mol1atm21" stroke="none"/>
                
            <line class="hi" id="mol1bnd14" stroke="#1FF01F" x1="6.875" x2="12.717" y1="38.079" y2="34.705"/>
            <line class="hi" id="mol1bnd15" stroke="#3050F8" x1="55.029" x2="50.002" y1="10.29" y2="13.1905"/>
            <line class="hi" id="mol1bnd15" stroke="#3050F8" x1="55.029" x2="50.002" y1="10.29" y2="13.1905"/>
            <line class="hi" id="mol1bnd16" stroke="#3050F8" x1="61.336" x2="66.3635" y1="10.29" y2="13.1905"/>
            <line class="hi" id="mol1bnd16" stroke="#3050F8" x1="61.336" x2="66.3635" y1="10.29" y2="13.1905"/>
            <line class="hi" id="mol1bnd18" stroke="#FF0D0D" x1="71.391" x2="71.391" y1="27.409" y2="21.75"/>
            <line class="hi" id="mol1bnd19" stroke="#FF0D0D" x1="68.109" x2="63.146" y1="33.224" y2="36.0875"/>
            <line class="hi" id="mol1bnd21" stroke="#90E050" x1="58.697" x2="63.337" y1="58.412" y2="54.519"/>
            <line class="hi" id="mol1bnd22" stroke="#90E050" x1="75.506" x2="71.7415" y1="59.601" y2="55.1135"/>
            <line class="hi" id="mol1bnd23" stroke="#90E050" x1="77.214" x2="72.5955" y1="42.878" y2="46.751999999999995"/>
        </g>
          
    </g>
    
</svg>
","Therapeutic Uses":"Anti-HIV Agents; Reverse Transcriptase Inhibitors","Title":"Efavirenz","UNII":"JE6H2O27P8","Wikidata":"Q422645","XLogP":4}